FDA Facility Issue May Delay Regeneron's EYLEA HD Launch

FDA flags Catalent facility producing Regeneron's EYLEA HD syringe. Canaccord maintains $850 target, highlighting Alzheimer's pipeline potential and GLP-1 combos.